Creso Pharma’s latest anibidiol shipment to Virbac makes over $200k in revenue
Health & Biotech
Health & Biotech
Link copied to
Special Report: Creso Pharma has delivered a large shipment of animal health product anibidiol to its multinational partner Virbac, making significant revenue in the process.
Creso Pharma (ASX:CPH) has delivered a large shipment of anibidiol® Plus to animal health multinational Virbac S.A. International at its headquarters in France.
This delivery generated revenue of CHF 127,000 ($215,000).
“Our ability to deliver this order on time in a challenging environment is a testament to the professionalism and capabilities of our strategic partner, Domaco DMH and our supply and logistic partners in Europe,” Creso cofounder and CEO Dr Miri Halperin Wernli said.
“We are pleased to be able to ensure ongoing supply to a growing base of veterinary doctors and pet owners who are using our anibidiol® line of products throughout Europe.”
Creso Pharma says it continues to be encouraged by the positive feedback received from veterinary doctors and pet owners, which was reflected in the growth in animal health product sales of over 700 per cent in 2019.
This delivery was achieved with the strong collaborative efforts of Creso’s strategic partner, Domaco DNH Switzerland, and its logistic partners in Europe who were able to ensure no interruption to Creso’s distribution chain, in spite of the challenges posed as a result of the global COVID-19 pandemic.
Creso Pharma developed the anibidiol® line for small, medium-sized and large pets to support the reduction of stress and help animals’ nervous systems to function well.
Pet owners report anibidiol® has also contributed to the management of pain and improved the vitality of their pets after one week of use in addition to normal feed.
Creso Pharma developed anibidiol® and has patented its granulated delivery system. anibidiol® is produced in Switzerland.